Nevertheless, the significant role of ESR1 mutations in endocrine resistance was not entirely recognized until 2013, when two independent studies confirmed that somatic ESR1 mutations are relatively common (10–50%) in endocrine therapy-resistant metastatic ER+ breast cancer patients [78,80]. This evidence concerns the gene ESR1 and breast cancer.